Alumis ALMS
NASDAQ ALMS
$9.90 +0.10 (+1.02%)
At close: Sep 10, 2026 · 4:00 PM EDT

Alumis (ALMS) Non Operating Income (2023 - 2026)

Alumis' (ALMS) quarterly Non Operating Income came in at $4.9 million in Q2 2026, down 97.45% year-over-year from $191.3 million in Q2 2025, and up 38.79% quarter-over-quarter from $3.5 million in Q4 2025.

Analysis

Alumis (ALMS) Non Operating Income (2023 - 2026) Analysis & Trends

Alumis (ALMS) has reported Non Operating Income for 4 consecutive years, with $4.9 million the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Non Operating Income fell 97.45% year-over-year to $4.9 million in Q2 2026; TTM through Jun 2026 was $204.2 million, a 0.6% increase from a year earlier, with the FY2025 full-year figure at $201.9 million, up 2996.43% from the prior year.
  • Non Operating Income was $4.9 million for Q2 2026 at Alumis, up from $3.5 million in the prior quarter.
  • Over five years, Non Operating Income peaked at $191.3 million in Q2 2025 and troughed at -$2.3 million in Q1 2024.
  • A 4-year average of $18.0 million and a median of $3.0 million in 2025 frame the typical range for Non Operating Income.
  • Across the five-year window, Non Operating Income slumped 127.59% in 2024 and jumped 52083.42% in 2025, its largest moves.
  • Over 4 years, Non Operating Income stood at $832000.0 in 2023, then jumped by 364.3% to $3.9 million in 2024, then dropped by 9.03% to $3.5 million in 2025, then surged by 38.79% to $4.9 million in 2026.
  • The last three Non Operating Income figures came in at $4.9 million (Q2 2026), $3.5 million (Q4 2025), and $4.5 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Op. Inc. (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn -73.00 Mn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 387.00 Mn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 234.30 Mn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn -
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn -53.64 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn -
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn -
10 Alumis 1.27 Bn 765.76 Mn - 4.88 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 4.88 Mn
Dec 31, 2025 3.51 Mn
Sep 30, 2025 4.54 Mn
Jun 30, 2025 191.30 Mn
Mar 31, 2025 2.57 Mn
Dec 31, 2024 3.86 Mn
Sep 30, 2024 5.28 Mn
Jun 30, 2024 -368,000.00
Mar 31, 2024 -2.26 Mn
Dec 31, 2023 832,000.00
Sep 30, 2023 382,000.00
Jun 30, 2023 1.33 Mn